Tarlatamab before and after surgery for recurrent high-grade glioma
Treatments studied
Part of Cancer clinical trials.
This trial studies whether giving the drug tarlatamab before and after surgery can help treat recurrent high-grade glioma (a type of brain cancer). It aims to see if this approach is safe and effective for patients who are eligible for surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a confirmed diagnosis of DLL3-positive high-grade glioma (a specific type of brain tumor).
- You must be a candidate for surgical removal of the tumor, and the surgery can be safely delayed for at least 2 weeks after your first study treatment.
- You must be in generally good health (able to do daily activities without significant help) and have adequate organ function (kidney, liver, heart, lungs, blood).
- You must not be taking more than a low dose of steroids (dexamethasone up to 4 mg daily) at the time of screening.
- You must not have an active autoimmune disease, HIV, active hepatitis B or C, or have received a live vaccine within 30 days before starting treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a new drug called tarlatamab is safe and effective for people with certain types of brain tumors that have an IDH mutation. You may be eligible if you have had up to 2 prior treatments after the tumor returned, and you are either having surgery to remove the tumor or the tumor cannot be removed.
This trial tests a new drug, Tarlatamab, for women whose gynecological neuroendocrine cancer has come back or spread. The drug targets a protein on cancer cells to help the immune system attack them. The study aims to see if it can shrink tumors and slow the disease.
This trial tests a new combination of two drugs (tarlatamab and temozolomide) for people with certain types of aggressive brain or central nervous system tumors that have come back or not responded to standard treatment. The hope is that this combination may work better against tumors that have a specific marker called DLL3.
This trial tests a new drug, tarlatamab, for people with small cell lung cancer that has spread to the brain. It aims to see if the drug can shrink brain tumors and help you live longer, especially if you have not had brain radiation before.
This trial tests a new drug called tarlatamab for people with advanced small cell or neuroendocrine cancers that started outside the lung (like in the stomach, bladder, or head and neck) and have grown after initial chemotherapy. It aims to see if this treatment can shrink or control the cancer.
This trial tests a new drug called tarlatamab for people with advanced small cell lung cancer that has worsened after one prior round of chemotherapy plus immunotherapy. It's designed for patients who are still active but may need extra support (ECOG 2).
Hear when a new High-Grade Glioma (HGG) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.